跳至主要内容
临床试验/EUCTR2011-001856-12-CZ
EUCTR2011-001856-12-CZ进行中(未招募)1 期

Early assessment of effectivness of neoadjuvant chemotherapy for carcinoma of the esophagus and esophago-gastric junction using FDG-PET/CT.

The Motol University Hospital0 个研究点开始时间: 2011年7月26日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • age 18-75 years, males and females
  • histologically verified adenocarcinoma of the esophagus or esophago-gastric junction or proximal stomach affecting cardia
  • no distant metastases or non-regional lymph node metastasis on computed tomography of chest and abdomen
  • cT1, N1, M0-1a or cT2-T4 (potentially resectable tumor), N0-1, M0-1a (TNM staging AJCC 6th edition) on EUS and CT
  • performance status 0-1 (WHO)
  • medically fit for elective esophagectomy after neoadjuvant chemotherapy
  • signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 150
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 100

排除标准

  • Patients with insulin-dependent diabetes mellitus or DM II on oral antidiabetics with glycemia level above 10 mmol/l
  • Patients with the finding of distant organ metastases at the inicial FDG-PET/CT will be excluded from the study
  • pregnant or nursing women

研究者

发起方
The Motol University Hospital

相似试验